Adaptimmune (ADAP) Down on End of Collaboration With Roche

2d ago, source: Zacks.com on MSN

Adaptimmune Therapeutics plc ADAP announced that its strategic collaboration with Roche’s RHHBY Genentech has been terminated ...

Adaptimmune, Genentech terminate collaboration to research, develop, and commercialize cancer-targeted allogeneic t-cell therapies

2d ago, source: Pharmabiz

Adaptimmune Therapeutics plc, a company redefining the treatment of solid tumour cancers with cell therapy, announced that its strategic collaboration with Genentech entered in 2021, has been ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript March 6, 2024 Adaptimmune Therapeutics plc isn't ...

Adaptimmune (ADAP) Down on End of Collaboration With Roche

2d ago, source: Nasdaq

Adaptimmune Therapeutics plc ADAP announced that its strategic collaboration with Roche’s RHHBY Genentech has been terminated. Shares of ADAP were down 10% on the news. Both companies ...

Adaptimmune Therapeutics PLC ADR

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adaptimmune Therapeutics plc (ADAP)

1mon ago, source: Yahoo Finance

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript March 6, 2024 Adaptimmune Therapeutics plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

Adaptimmune Therapeutics PLC ADR

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adaptimmune Therapeutics Plc - ADR

27d ago, source: U.S. News & World Report

Analysts say these cheap stocks have plenty of upside.

Adaptimmune Therapeutics PLC ADR

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Adaptimmune Therapeutics PLC ADR

1mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...